Genomic Tests For Warfarin Could Gain Coverage With Study Participation
This article was originally published in The Pink Sheet Daily
Under a CMS proposal, genomic testing to predict warfarin response would receive Medicare coverage in the context of a clinical trial comparing the frequency of five kinds of adverse events with and without the tests.
You may also be interested in...
CMS opened a national coverage analysis Aug. 4 to collect data on whether pharmacogenetic testing to determine sensitivity to the anti-clotting drug warfarin really improves overall health outcomes
FDA's drug and device centers are increasingly putting their weight behind the use of genetic tests to determine proper dosing of the anti-clotting drug warfarin, but convincing doctors is proving a bigger challenge
FDA is updating the label for the anti-clotting drug warfarin to inform physicians and patients about the usefulness of genetic testing before beginning therapy, but the agency will wait for data from ongoing studies of the tests before adding stronger recommendations for the tests